To estimate the risk of major congenital anomalies among pregnancies exposed to Cymbalta

To estimate risk of recognized spontaneous abortions, stillbirths, elective terminations, minor congenital anomalies, and any serious adverse pregnancy outcomes among pregnancies exposed to Cymbalta and their live births during the first year of life

To examine any potential impact of Cymbalta use while breastfeeding on the infant during the first year of life

To compare the risk of major congenital anomalies among pregnancies exposed to Cymbalta to an appropriate comparator(s) such as the Centers for Disease Control and Prevention (CDC) Metropolitan Atlanta Congenital Defects Program (MACDP)

484

Female

18 Years and older (Adult, Senior)

NCT01074151

12938F1J-MC-B034

July 2009

December 2020

December 2020

February 24, 2010

December 8, 2017

The Cymbalta Pregnancy Registry Call CenterWilmington, North Carolina, United States